Minimal residual disease (MRD) screening is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-free DN… Read More

Minimal residual disease (MRD) identification is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-fr… Read More

Liquid biopsy has emerged as a potent approach for monitoring minimal residual disease (MRD) in lymphoma. Unlike traditional tissue biopsies, which are invasive, liquid biopsy analyzes biomarkers present in bodily fluids such as serum. This gentle procedure allows for repeated assessment of MRD levels, delivering valuable information to guide manag… Read More